In order to search new pathways for technology and marketing integration, scale up laboratory work to industrial production, develop technological platforms with international guidelines for new drugs, and offer services to domestic trades, in 1996, authorized by the Ministry of Science and Technology of China (MOST), the "National Engineering Research Center for Development of New Drugs" (hereinafter referred to as "Engineering Center") was founded based on the Institute of Materia Medica, Chinese Academy of Medical Sciences (IMM, CAMS). In 2002,Beijing Collab Pharma Co., Ltd .(hereinafter referred to as "Collab") was incorporated by the Engineering Center in Beijing, as a market-oriented operation. Over more than twenty years of development, the company focusing on the research of the intermediate links of laboratory and market transformation, has established multiple technological platforms for drug synthesis, formulation research and analytical testing. Also, a number of different types of drug R&D pilot bases have been set up, and a drug R&D management system with clinical application and technology transformation as the core has been built, forming a pharmaceutical R&D pattern that integrates innovative medicine and generic drug development, drug improvement, technology transfer, and technical services.
